Early Data On JAK Inhibitor Show Incyte And Lilly Are In The Race In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
It's early days in the oral RA race, but data so far suggest the Incyte/Lilly compound could hold its own against Pfizer's front-runner tasocitinib.
You may also be interested in...
Pfizer retains its lead in race to bring a novel oral RA drug to market
No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.